Aevi Genomic Medicine, Inc. reported consolidated earnings results for the second quarter and six months ended June 30, 2018. For the quarter, the company reported net loss of $8,191,000 or $0.14 per share against $8,033,000 million or $0.22 per share a year ago. Operating loss of $8,251,000 against $8,036,000 a year ago. For the six months, the company reported operating loss of $16,986,000 against $18,971,000 a year ago. Net loss was $16,900,000 or $0.28 per basic and diluted share against $18,950,000 or $0.51 per basic and diluted share a year ago.